Orlistat

Orlistat is a non-systemic effects of anti-obesity drugs for specific gastrointestinal lipase inhibitor, combined with dietary restrictions can help promote weight loss and prevent weight regain.

General Details

Fat Reduce and Weight Loss Drugs Orlistat CAS 96829-58-2 Fat Burning Steroid

 

Quick details:
Model NO.:96829-58-2

Product Name:Orlistat
Other Name:Orlistat

CAS No.:96829-58-2
Assay:98%

M.F.:C18H22O2
M.W.:270.37

Appearance:White Power
Paacking:Foil Bag

Delivery:Within 24hours After Your Payment
Express:TNT, UPS, DHL, EMS, Hkems, FedEx

Export Markets:Global

Packing:Foil Bag
Standard:GMP

Origin:China
HS Code:3001200020

Production Capacity:1000kg/Mouth

 

Orlistat  Description :

 

Orlistat is a non-systemic effects of anti-obesity drugs for specific gastrointestinal lipase

inhibitor, combined with dietary restrictions can help promote weight loss and prevent

weight regain. Gastrointestinal lipases break down fats in the gastrointestinal tract is

necessary enzymes, orlistat inhibits stomach, pancreatic and hydroxy acid esterase,

primarily through the stomach, small intestine lumen of the stomach and pancreatic

lipases active serine parts form a covalent bond, to inactivate enzymes play a therapeutic

role. Inactivate enzymes can not be fat in food (mainly triglyceride) hydrolysis of absorbable

and non-esterified fatty acid monoacylglycerol. No decomposition of triglycerides (about 30%

of the amount of feed) can not be absorbed in the intestine, thereby reducing caloric intake,

body weight under control. Systemic absorption of the drug efficacy can play without going

through. Orlistat for weight loss, and reduce the risk factors associated with obesity and other

diseases associated with obesity (including high cholesterol, type 2 diabetes, impaired glucose

tolerance, hyperinsulinemia, hypertension) in morbidity, and reduce the fat content of

organs.

 

Application:

The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data

from clinical trials suggest that people given orlistat in addition to lifestyle modifications,

such as diet and exercise, lose about 2-3 kilograms (4.4

6.6 lb) more than those not taking the drug over the course of a year.Orlistat also

modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes,

whether due to weight loss itself or to other effects; in a large randomized controlled trial,

orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment

effects), which can include steatorrhea (oily, loose stools). These decrease with time,

however, and are the most frequently reported adverse effects of the drug. In the United

States and the European Union, orlistat is available for sale without a prescription. Over-the

counter approval was controversial in the United States, with consumer advocacy group

Public Citizen repeatedly opposing it on safety and efficacy grounds. Generic formulations

of orlistat are available in some countries. A prescription is needed for use in Australia.

 

Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed

as a prescription drug under the trade name by Roche in most countries, and is sold

over-the-counter as by GlaxoSmithKline in the United Kingdom and the United States.Its primary

function is preventing the absorption of fats from the human diet by acting as a lipase

inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a

healthcare provider-supervised reduced-calorie diet.
Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases

isolated from the bacterium Streptomyces toxytricini.However, due to its relative simplicity

and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data

from clinical trials suggest that people given orlistat in addition to lifestyle modifications,

such as diet and exercise, lose about 2-3 kilograms (4.46.6 lb) more than those not

taking the drug over the course of a year.Orlistat also modestly

reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due

to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was

found to reduce the incidence of diabetes by nearly 40% in obese people.

Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment

effects), which can include steatorrhea (oily, loose stools). These decrease with time, however,

and are the most frequently reported adverse effects of the drug.In the United States and

the European Union,orlistat is available for sale without a prescription. Over-

the counter approval was controversial in the United States, with consumer advocacy group

Public Citizen repeatedly opposing it on safety and efficacy grounds.Generic formulations of

orlistat are available in some countries. In Australia it is listed as an S3 medication, which

means it’s available over the counter in pharmacies.At times, such as in spring 2012, orlistat

has come into short supply, with consequent price increases because of nonavailability of one

of the drug’s components.
Medical uses

Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat

varies.In one year clinical trials, between 35.5% and 54.8% of subjects achieved a 5%

or greater decrease in body mass, although not all of this mass was necessarily fat. Between

16.4% and 24.8% achieved at least a 10% decrease in body fat.After orlistat was stopped, a

significant number of subjects regained weight-

up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese

population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).

Long-term use of orlistat also leads to a modest

reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic

blood pressure respectively).

 

 

Contact Now

  • 6 + 9 =

 

Order Enquiry

Contact Now

  • 6 + 18 =
Comments

Leave a Reply

Your email address will not be published.